For most biologics, the manufacturer would have requested and got a patent term extension under 35 USC 156. The practical limit seems to be 14 yrs from date of approval. This would be an easy way of looking at upcoming expiry I guess.
(Bold text indicates recombinant and monoclonal antibody products.) Note: This list includes biologics developed by biotechnology companies and pharmaceutical companies, as well as small-molecule products developed by biotechnology companies, and other selected small-molecule or tissue-engineered products. This list covers approvals and new indications from 1982 through 2005. Selected 2006 approvals (through Oct. 31) are also included.
Market Data 
Markets 
AI
